Omnicell (OMCL) Non-Current Deffered Revenue (2010 - 2026)
Omnicell's (OMCL) quarterly Non-Current Deffered Revenue came in at $59.5 million in Q2 2026, down 26.02% year-over-year from $80.4 million in Q2 2025, and down 5.63% quarter-over-quarter from $63.1 million in Q1 2026.
Analysis
Omnicell (OMCL) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends
Omnicell (OMCL) has reported Non-Current Deffered Revenue for 17 consecutive years, with $59.5 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non-Current Deffered Revenue fell 26.02% year-over-year to $59.5 million in Q2 2026; TTM through Jun 2026 was $59.5 million, a 26.02% decrease from a year earlier, with the FY2025 full-year figure at $63.3 million, down 16.91% from the prior year.
- Non-Current Deffered Revenue was $59.5 million for Q2 2026 at Omnicell, down from $63.1 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $80.4 million in Q2 2025 and troughed at $24.0 million in Q1 2022.
- A 5-year average of $56.4 million and a median of $61.3 million in 2026 frame the typical range for Non-Current Deffered Revenue.
- Across the five-year window, Non-Current Deffered Revenue surged 204.27% in 2022 and decreased 26.02% in 2026, its largest moves.
- Over 5 years, Non-Current Deffered Revenue stood at $37.4 million in 2022, then soared by 56.81% to $58.6 million in 2023, then climbed by 29.85% to $76.1 million in 2024, then fell by 16.91% to $63.3 million in 2025, then dropped by 5.91% to $59.5 million in 2026.
- The last three Non-Current Deffered Revenue figures came in at $59.5 million (Q2 2026), $63.1 million (Q1 2026), and $63.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 187.42 Bn | 182.47 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 129.78 Bn | 124.69 Bn | 1.96 Bn | - |
| 3 | Medtronic | 120.53 Bn | 112.33 Bn | 6.34 Bn | - |
| 4 | Stryker | 116.28 Bn | 112.80 Bn | 4.50 Bn | - |
| 5 | Boston Scientific | 69.29 Bn | 68.99 Bn | 3.85 Bn | - |
| 6 | Edwards Lifesciences | 51.83 Bn | 47.68 Bn | 1.35 Bn | - |
| 7 | Alcon | 34.36 Bn | 32.91 Bn | 1.68 Bn | - |
| 8 | Dexcom | 33.17 Bn | 31.23 Bn | 830.00 Mn | - |
| 9 | Resmed | 32.94 Bn | 31.47 Bn | 861.22 Mn | 170.95 Mn |
| 10 | Omnicell | 1.57 Bn | 1.28 Bn | 152.94 Mn | 59.52 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 59.52 Mn |
| Mar 31, 2026 | 63.07 Mn |
| Dec 31, 2025 | 63.25 Mn |
| Sep 30, 2025 | 66.72 Mn |
| Jun 30, 2025 | 80.45 Mn |
| Mar 31, 2025 | 78.37 Mn |
| Dec 31, 2024 | 76.12 Mn |
| Sep 30, 2024 | 69.81 Mn |
| Jun 30, 2024 | 67.93 Mn |
| Mar 31, 2024 | 65.20 Mn |
| Dec 31, 2023 | 58.62 Mn |
| Sep 30, 2023 | 55.10 Mn |
| Jun 30, 2023 | 48.80 Mn |
| Mar 31, 2023 | 42.44 Mn |
| Dec 31, 2022 | 37.39 Mn |
| Sep 30, 2022 | 34.52 Mn |
| Jun 30, 2022 | 24.20 Mn |
| Mar 31, 2022 | 24.04 Mn |
| Dec 31, 2021 | 20.20 Mn |
| Sep 30, 2021 | 14.14 Mn |